Tag: PharmaIndustry

• 

  Natco Pharma Secures USFDA Approval for Bosentan Tablets for Oral Suspension (32mg): A Game-Changer in PAH Treatment

  Natco Pharma has received USFDA approval for its generic Bosentan tablets for oral suspension (32mg), a key treatment for pediatric pulmonary arterial hypertension (PAH). With First-to-File status, Natco is poised to capture significant market share through a 180-day exclusivity period. This approval opens new opportunities for Natco and its partner Lupin Pharmaceuticals in the growing U.S. pediatric PAH market, addressing a critical need for easier-to-administer treatments.